Since p53 represses MAPK4 expression by activating DCP1B, we tested whether the p53 agonist APG-115 and the PI3K inhibitor Alpelisib have a synergistic effect in inhibiting the proliferation of NSCLC cells. Here, MAPK4 is linked to non-small cell lung carcinoma.